Antineoplastic extravasation is the inadvertent unintentional instillation or leakage of these agents into the perivascular and subcutaneous spaces during their administration.1Extravasation is considered an oncology emergency, as can be associated with drug-induced tissue damage that can
result in severe iatrogenic consequences for patients, such as tissue necrosis.2,3 Extravasation can also compromise on cology patient´s health outcomes and quality of life,1,4 due to treatment delays and tissue damage complications. The incidence of extravasations reported in the literature is between 0.1% and 6.0% in peripheral venous lines and 0.26% to 4.7% in central venous lines.5 The improvement in preventing measures implemented in recent years considering patient´s related factors, technique related factors and drug related variables associated with an increased risk of drug induced tissue damage,5 has reduce the incidence and severity of this adverse event, both in peripheral and central lines.6 But despite these progresses, extravasation management remains an area where good quality evidence is very limited.
